Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:INCRNASDAQ:NGNENASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.21+0.6%$2.93$2.46▼$4.15$270.43M0.18315,434 shs389,553 shsINCRInterCure$1.50+0.7%$1.49$1.17▼$2.62$67.90M1.2226,609 shs4,477 shsNGNENeurogene$18.42-2.9%$16.26$6.88▼$74.49$281.82M1.57249,469 shs152,132 shsTNXPTonix Pharmaceuticals$34.92-5.5%$25.76$6.76▼$137.25$235.28M2.09923,131 shs412,645 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals+0.63%-0.31%+17.15%+1.26%-9.07%INCRInterCure-0.60%+1.08%-2.53%-4.70%-36.93%NGNENeurogene-2.90%-14.64%+2.39%+19.46%-53.95%TNXPTonix Pharmaceuticals-5.55%-7.47%+24.71%+112.02%-68.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals3.3654 of 5 stars3.34.00.00.02.72.51.3INCRInterCure0.3817 of 5 stars0.03.00.00.01.90.00.6NGNENeurogene3.475 of 5 stars4.43.00.00.02.02.50.6TNXPTonix Pharmaceuticals3.3546 of 5 stars3.52.00.00.03.13.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0086.92% UpsideINCRInterCure 0.00N/AN/AN/ANGNENeurogene 2.75Moderate Buy$46.17150.63% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,575.26% UpsideCurrent Analyst Ratings BreakdownLatest INCR, AVIR, TNXP, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.005/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AINCRInterCure$64.55M1.06N/AN/A$2.36 per share0.64NGNENeurogene$930K282.44N/AN/A$20.89 per share0.88TNXPTonix Pharmaceuticals$10.09M25.47N/AN/A$31.82 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)NGNENeurogene-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest INCR, AVIR, TNXP, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.3319.33INCRInterCure0.151.781.15NGNENeurogeneN/A9.099.09TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%INCRInterCure8.34%NGNENeurogene52.37%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%INCRInterCureN/ANGNENeurogene9.92%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableINCRInterCure35045.57 millionN/AOptionableNGNENeurogene9014.26 million12.85 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableINCR, AVIR, TNXP, and NGNE HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Trading 9.9% Higher - Still a Buy?June 16 at 2:59 PM | marketbeat.comTonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A BuyJune 16 at 11:56 AM | seekingalpha.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...June 16 at 7:56 AM | gurufocus.comTonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock NewsJune 16 at 7:56 AM | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...June 16 at 7:14 AM | gurufocus.comTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025June 16 at 7:00 AM | globenewswire.comTwo Sigma Investments LP Makes New $66,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14, 2025 | marketbeat.comMillennium Management LLC Lowers Holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 14, 2025 | marketbeat.comTonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim” Hunter, to Board of DirectorsJune 13, 2025 | manilatimes.netTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.8% - Time to Sell?June 13, 2025 | marketbeat.comTonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?June 13, 2025 | seekingalpha.comTonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of DirectorsJune 13, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 10.1% - Here's What HappenedJune 12, 2025 | marketbeat.comTonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not PessimisticJune 12, 2025 | msn.comTonix Pharmaceuticals stock falls after announcing $225 million share offeringsJune 12, 2025 | investing.comTonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares TumbleJune 12, 2025 | benzinga.comTonix Shares Fall After Entering Sales, Purchase AgreementsJune 12, 2025 | marketwatch.comTonix Pharmaceuticals files $500M mixed securities shelf, shares down 15%June 12, 2025 | seekingalpha.comTonix Pharma Signs Major Sales Agreements for FundingJune 11, 2025 | tipranks.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 1.9% Higher - What's Next?June 11, 2025 | marketbeat.comTonix Pharmaceuticals Announces Presentation at the 2025 BIO International ConventionJune 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative GainsNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherSalesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayScience Applications International Is a Wicked Hot Buy in JuneBy Thomas Hughes | June 9, 2025View Science Applications International Is a Wicked Hot Buy in JuneINCR, AVIR, TNXP, and NGNE Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.21 +0.02 (+0.63%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$3.21 0.00 (0.00%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.InterCure NASDAQ:INCR$1.50 +0.01 (+0.74%) Closing price 06/17/2025 03:59 PM EasternExtended Trading$1.50 +0.00 (+0.27%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Neurogene NASDAQ:NGNE$18.42 -0.55 (-2.90%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$18.43 +0.01 (+0.05%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$34.92 -2.05 (-5.55%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$34.56 -0.37 (-1.05%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? Can Luckin and Dutch Bros Take Market Share From Starbucks? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
